PL378566A1 - Ligandy dla białek wiążących TGF-beta i ich zastosowania - Google Patents

Ligandy dla białek wiążących TGF-beta i ich zastosowania

Info

Publication number
PL378566A1
PL378566A1 PL378566A PL37856604A PL378566A1 PL 378566 A1 PL378566 A1 PL 378566A1 PL 378566 A PL378566 A PL 378566A PL 37856604 A PL37856604 A PL 37856604A PL 378566 A1 PL378566 A1 PL 378566A1
Authority
PL
Poland
Prior art keywords
tgf
complex
beta binding
ligands
binding proteins
Prior art date
Application number
PL378566A
Other languages
English (en)
Inventor
David G. Winkler
John Latham
John Skonier
Diana Shpektor
Trenton Hayes
James Geoghegan
Original Assignee
Celltech R & D, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celltech R & D, Inc. filed Critical Celltech R & D, Inc.
Publication of PL378566A1 publication Critical patent/PL378566A1/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/51Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
PL378566A 2003-03-14 2004-03-12 Ligandy dla białek wiążących TGF-beta i ich zastosowania PL378566A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US45525303P 2003-03-14 2003-03-14

Publications (1)

Publication Number Publication Date
PL378566A1 true PL378566A1 (pl) 2006-05-02

Family

ID=33029975

Family Applications (2)

Application Number Title Priority Date Filing Date
PL378566A PL378566A1 (pl) 2003-03-14 2004-03-12 Ligandy dla białek wiążących TGF-beta i ich zastosowania
PL04720380T PL1608399T3 (pl) 2003-03-14 2004-03-12 Kompleks sklerostyny i nogginy lub chordyny, oraz czynniki modulujące tworzenie tego kompleksu

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL04720380T PL1608399T3 (pl) 2003-03-14 2004-03-12 Kompleks sklerostyny i nogginy lub chordyny, oraz czynniki modulujące tworzenie tego kompleksu

Country Status (15)

Country Link
US (1) US7226902B2 (pl)
EP (1) EP1608399B1 (pl)
JP (1) JP4660471B2 (pl)
AT (1) ATE540977T1 (pl)
AU (1) AU2004222317B2 (pl)
CA (1) CA2519131C (pl)
CY (1) CY1112797T1 (pl)
DK (1) DK1608399T3 (pl)
ES (1) ES2379689T3 (pl)
MX (1) MXPA05009805A (pl)
NZ (1) NZ542587A (pl)
PL (2) PL378566A1 (pl)
PT (1) PT1608399E (pl)
SI (1) SI1608399T1 (pl)
WO (1) WO2004082608A2 (pl)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ552959A (en) 1998-11-27 2008-06-30 Darwin Discovery Ltd Compositions and methods for increasing bone mineralization
EP1636270B1 (en) * 2003-06-16 2016-07-20 UCB Pharma S.A. Antibodies specific for sclerostin and methods for increasing bone mineralization
US8461155B2 (en) * 2003-09-22 2013-06-11 University Of Connecticut Sclerostin and the inhibition of WNT signaling and bone formation
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
US7592429B2 (en) * 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
AU2006289667A1 (en) * 2005-09-08 2007-03-15 Apollo Life Sciences Limited Noggin and chimeric molecules thereof
DK2069558T3 (da) 2006-10-02 2013-08-05 Sea Lane Biotechnologies Llc Design og konstruktion af forskelligartede syntektiske peptid- og polypeptidbiblioteker
WO2008061013A2 (en) * 2006-11-10 2008-05-22 Amgen Inc. Antibody-based diagnostics and therapeutics
US20100015665A1 (en) * 2006-11-10 2010-01-21 Ucb Pharma S.A. Antibodies and diagnostics
WO2008092894A1 (en) * 2007-02-02 2008-08-07 Novartis Ag Modulators of sclerostin binding partners for treating bone-related disorders
CL2008002775A1 (es) 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
CA2707400A1 (en) * 2007-12-14 2009-06-25 Amgen Inc. Method for treating bone fracture with anti-sclerostin antibodies
CA2742871C (en) * 2008-11-13 2018-10-23 Herb Lin Methods and compositions for regulating iron homeostasis by modulation of bmp-6
KR101163171B1 (ko) * 2009-01-20 2012-07-19 (주)케어젠 노긴?유래 펩타이드 및 그의 용도
DK3195880T3 (da) 2010-05-14 2020-03-02 Amgen Inc Højkoncentrerede anti-sclerostin-antistofformuleringer
JP2014509588A (ja) 2011-03-01 2014-04-21 アムジエン・インコーポレーテツド 二特異性結合剤
SG10201701634PA (en) 2011-03-25 2017-04-27 Amgen Inc Anti - sclerostin antibody crystals and formulations thereof
ES2667554T3 (es) 2011-08-04 2018-05-11 Amgen Inc. Método para el tratamiento de los defectos de espacio óseo
SG10201509629QA (en) 2011-12-28 2015-12-30 Amgen Inc Method Of Treating Alveolar Bone Loss Through The Use Of Anti-Sclerostin Antibodies
JP6770312B2 (ja) 2012-07-05 2020-10-14 ユセベ ファルマ ソシエテ アノニム 骨疾患の治療
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
MA41142A (fr) 2014-12-12 2017-10-17 Amgen Inc Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
GB201604124D0 (en) 2016-03-10 2016-04-27 Ucb Biopharma Sprl Pharmaceutical formulation
JP2020502218A (ja) 2016-12-21 2020-01-23 メレオ バイオファーマ 3 リミテッド 骨形成不全症の処置における抗スクレロスチン抗体の使用
CA3093457A1 (en) 2018-03-30 2019-10-03 Amgen Inc. C-terminal antibody variants

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5846770A (en) * 1994-11-22 1998-12-08 Genetics Institute, Inc. DNA molecules encoding human chordin
CA2220912A1 (en) 1995-06-05 1996-12-12 Gregg A. Hastings Human ccn-like growth factor
US5989909A (en) * 1997-09-26 1999-11-23 Millennium Biotherapeutics, Inc. Huchordin and uses thereof
WO1998046588A2 (en) * 1997-04-11 1998-10-22 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
US6075007A (en) * 1997-07-17 2000-06-13 Regeneron Pharmaceuticals, Inc. Modified noggin polypeptide and compositions
DE69941291D1 (de) 1998-03-30 2009-10-01 Dow Agrosciences Llc Änderung der fettsäure-zusammensetzung in pflanzen durch expression einer aspergillus nidulans delta-9 coa desaturase
NZ552959A (en) * 1998-11-27 2008-06-30 Darwin Discovery Ltd Compositions and methods for increasing bone mineralization
MXPA02008506A (es) 2000-03-02 2002-12-13 Amgen Inc Moleculas semejantes a chordin-2 y sus usos.

Also Published As

Publication number Publication date
ATE540977T1 (de) 2012-01-15
AU2004222317B2 (en) 2010-08-19
NZ542587A (en) 2008-05-30
EP1608399B1 (en) 2012-01-11
PL1608399T3 (pl) 2012-09-28
CY1112797T1 (el) 2016-02-10
SI1608399T1 (sl) 2012-05-31
JP2006522103A (ja) 2006-09-28
AU2004222317A1 (en) 2004-09-30
WO2004082608A3 (en) 2005-01-20
DK1608399T3 (da) 2012-04-02
US20050085418A1 (en) 2005-04-21
WO2004082608A9 (en) 2005-03-17
US7226902B2 (en) 2007-06-05
WO2004082608A2 (en) 2004-09-30
MXPA05009805A (es) 2006-04-18
CA2519131A1 (en) 2004-09-30
JP4660471B2 (ja) 2011-03-30
ES2379689T3 (es) 2012-04-30
CA2519131C (en) 2014-07-08
PT1608399E (pt) 2012-04-13
EP1608399A2 (en) 2005-12-28

Similar Documents

Publication Publication Date Title
PL378566A1 (pl) Ligandy dla białek wiążących TGF-beta i ich zastosowania
CY1124802T1 (el) Δεσμευτικοι παραγοντες σκληροστινης
RS20050934A (en) Antibodies specific for sclerostin and methods fo r increasing bone mineralization
MEP3108A (xx) Kompozicije i postupci za povećanje mineralizacije kostiju
MY174493A (en) Binding agents
MX2007008017A (es) Polipeptidos que se ligan a br3 y usos de los mismos.
EA200801621A1 (ru) Антитела, направленные на her-3, и их применение
EA200700847A1 (ru) Материалы, связывающие прионные белки, и способы их применения
TW200745159A (en) IL-6 binding proteins
WO2006087163A3 (en) Novel in vitro methods for studying receptors recognizing volatile compounds
EA200800205A1 (ru) Кальций-пептидный компонент
EA200500624A1 (ru) Промотор для il-18bp, его получение и применение
TW200718711A (en) Polypeptides that bind BR3 and uses thereof
WO2006008266A3 (en) Factor xi-binding proteins
WO2007050554A3 (en) Methods for identifying compounds that modulate phb domain protein activity and compositions thereof
WO2004070347A3 (en) Screening for modulators of fat storage
UA115859C2 (uk) Розчинний поліпептид, який зв'язує активін а, та композиція, що його містить
WO2005040208A3 (en) Peptides derived from heat shock proteins binding toll-like receptors 2 and 4 and their use
SE0401166D0 (sv) Method for protein protection